IVZ II SP500 Eq We UCITS ETF AC GBP 30 April 2021 NAV/per Shares in Net Asset share Funds Date ISIN code Issue Currency Value Base Invesco S&P 500 Equal Weight UCITS ETF Acc 29/04/2021...
IVZ II SP500 Eq We UCITS ETF AC GBP 28 April 2021 NAV/per Shares in Net Asset share Funds Date ISIN code Issue Currency Value Base Invesco S&P 500 Equal Weight UCITS ETF Acc 19/04/2021...
IVZ II SP500 Eq We UCITS ETF AC GBP 28 April 2021 NAV/per Shares in Net Asset share Funds Date ISIN code Issue Currency Value Base Invesco S&P 500 Equal Weight UCITS ETF Acc 27/04/2021...
IVZ II SP500 Eq We UCITS ETF AC GBP 19 April 2021 NAV/per Shares in Net Asset share Funds Date ISIN code Issue Currency Value Base Invesco S&P 500 Equal Weight UCITS ETF Acc 18/04/2021...
Company Signs Long-term Supply Agreement for Pharmaceutical D-tagatose BETHESDA, Md., Jan. 12 /PRNewswire-FirstCall/ -- Spherix Inc. (Nasdaq SPEX), an innovator in biotechnology for diabetes...
BETHESDA, Md., Jan. 11 /PRNewswire-FirstCall/ -- Spherix Inc. (NASDAQ: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services...
BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (NASDAQ:SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting...
BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (NASDAQ:SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting...
BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (NASDAQ:SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting...
BETHESDA, Md., Sept 10 /PRNewswire-FirstCall/ -- Spherix Incorporated (NASDAQ:SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | SP |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約